NFKB1 and mantle cell lymphoma: Though CLL cells on ibrutinib have a decreased NFκB binding to DNA elements, activating an alternative NFκB pathway by genetic changes is another mechanism responsible for ibrutinib resistance, mostly in MCL (65).